RNA interference: the role in antiviral immunity and immune memory

Muratkhodjaev J.N. and Aripova T.U.

Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Uzbekistan.

Correspondence to: Muratkhodjaev Javdat, e-mail: javdat_m@yahoo.com

Abstract

The role of innate immunity in neutralization of viral infections (including COVID-19) and forming long-lasting and specific immune memory is considered. It is assumed that antiviral protection is generated by the mechanism of RNA interference (RNAi) and is based on the presence of specific viral patterns in the DNA library of the host cells.

“Memory” of innate immunity and antiviral response

It is well known that innate immunity also has the ability to memorize and learn (1-10). Plants are capable of forming the so-called systemic acquired resistance (SAR). It has been demonstrated that a primary infectious agent causes systemic resistance to repeated use of the same or similar agents (1). In invertebrate metazoans, protective innate immune responses are also modulated by previous exposure to various infectious agents (2–5). Interestingly, such enhanced reactivity of the invertebrate immune system can last a long time and has been found active in the offspring up to the third generation (7). Furthermore, among vertebrates, it has been clearly demonstrated that the innate component contributes to the formation of immune memory. An increase insensitivity of macrophages, monocytes and NK-cells to the repeated exposures of the pathogens is well documented phenomenon. Epigenetic changes in these effector cells are noted (8,9).

When considering antiviral defense mechanisms in the living kingdoms bacteria with its very effective yet smart CRISPR-Cas system has vowed scientists in our understanding of the complexity of cellular capacity to fight bacteriophages, bacteria’s viruses. A close analogue of such a protective system in eukaryotes is RNA interference (11). Plants and invertebrates make extensive use of this mechanism against viruses (12-15). Vertebrates, on the other hands, in addition to the antiviral RNA-i system (16-19) employ an interferon-activated antiviral system (20, 29-30). This protein-based defense system effectively combats viral infections, but it also blocks the operation of the anti-virus RNA-I system (21, 31-34). An analysis of published data allows us to shed a light to this contradiction and explain the phenomenon of long-term antiviral memory.

Hypothesis of generation specific antiviral memory by innate immune system

It has been shown that exogenous viral RNAs are cleaved in the cytoplasm by the Dicer enzyme into short fragments of about 20 bases in length, called small interfering RNAs (siRNAs) (22). Notably, these siRNAs by themselves act as active components of RNA-i. However, in order to
form long-lasting memory those fragments must be reverse-transcribed and then inserted into host-cell DNA. The very existence of such mechanisms has been described in the research of retrotransposons and pseudogenes (23-24), where intracellular reverse transcriptase ORF2 has been implemented in transforming cytoplasmic RNA and retroelement transcripts into complementary DNA parts. Moreover, those elements account to almost half of human DNA in the cells (25, 26). It is tempting to assume then that at least some parts of human DNA are coded DNA fragments of virus genome. This is some sort of “black list” of nucleotide sequences, prohibited for cell translation. After transcription of these sequences mRNA is then cleaved by the Drosha nuclease into micro RNA (miRNAs) sized by 21-23 length fragments. Micro RNAs has been frequently observed during infections caused by both DNA and RNA viruses (16). Those interfering RNAs no matter how they were formed, either by the Dicer (siRNA) activity or by Drosha (miRNA), would bind with RNA-induced silencing complex (RISC). Active RISC ensures binding between interference RNA and a complementary viral sequence and consequently potentiates cutting a viral RNA by aid of Argonaute protein, ultimately inhibiting translation and/or RNA deadenyaltion (27, 28). When re-infected RISC system is readily alert to degrade viral RNA or to inhibit viral protein translation. This is a proposed mechanism of antiviral immune memory in a nutshell.

In regards to the above mentioned antagonism between interferon and RNA-i protective system, again a closer look into localization of virus infection might give a clue. When viruses enter the cells interferon release is triggered. Interferons signal cascades of protective responses including apoptosis (29-30). Neighboring cells react to the interferon signals by switching them into “alarm mode”, which is usually blocks DICE/Drosha-RISC mechanism (31-34). However, as it turns out, this is not a case with actively proliferating and unipotent cells. (35). First line of cells that encounter virus entry is usually well differentiated surface epithelial or endothelial cells. They deal with the small virus load via interferon induced protection (29-35) and they do not participate in forming specific infection memory. True immune memory is formed only in unipotent precursor cells when either virus enters in them or interference RNAs. Only de novo formed differentiated surface cells will possess specific antiviral memory giving them a powerful tool to effectively eliminate additional loads of virus. Maturation of the novel endothelial and epithelial cells usually takes several days which constitutes a required time for forming specific antiviral memory. It also mean that this memory is local in its nature, and in order to have a systemic memory multipotent cells should be involved. Furthermore, for innate immunity being able to protect further generations or off-spring, germ line cells should be impacted as well.

Therefore, in fact there is no any antagonism in the two antiviral protection systems of innate immunity. It all depends on the level of cell differentiation and location of these cells.

Discussion

The above described mechanism of forming immune memory, by all means does not down value development of acquired immunity via specific CD4, CD8 cells along with humoral antibody-based antiviral immunity. This function of acquired immunity is well known, although the main role of this additional mechanisms in vertebrates might lie with the preservation of the integrity of their own cells, control over their change during aging and destruction processes (36-38). From this point, antibodies are produced against all antigens that a body encounters, including any viral proteins. However, sometimes such “antiviral” antibodies are rather more harmful then
protective. This is evident with the phenomenon of antibody-dependent enhancement (ADE) of the infection (39-42). In ADE virus not only infects susceptible cells through appropriate receptor but is able to hijack virus-specific antibodies to easily traffic virus bodies inside the monocytes/macrophages, granulocytes, platelets, mast and many more host cells through interaction with Fc and/or complement receptors (40). There are numerous examples of ADE, triggered by alpha- and beta-coronaviruses (43,44). Primates, vaccinated with modified Ankara vaccine virus encoding the full-length SARS-CoV glycoprotein, despite of low viral loads suffered from severe lung injury due to ADE (44). ADE phenomenon has been observed on the animal models of SARS and MERS (40). It has been shown that SARS-CoV-1 is capable to enter macrophages via antibody dependent route and even replicate in those cells (45, 46).

In connection with the foregoing, it is necessary to make adjustments to the assessment of herd immunity to COVID-19, which is at the moment traditionally based only on the measurement of the neutralizing antibodies titers. Another tool for this assessment should be DNA tests confirming the formation of new sequences in human cells corresponding to SARS-CoV-2 RNA. Future vaccines against SARS-CoV-2, the prospects of which are still remain elusive (49, 50), will also have to pass the same evaluation of effectiveness. It is necessary to draw the attention of medical community, especially practitioners to the role of innate immunity, which is especially important in the current COVID-19 pandemic.

**Conclusion**

To form long-term and specific antiviral memory the human body actively uses the mechanism of RNA interference, inserting for this purpose the nucleotide sequences corresponding to encountered viruses into the DNA of host cells.

**References**

1. Reimer-Michalski EM, Conrath U. Innate immune memory in plants. SeminImmunol (2016) 28:319–27. doi:10.1016/j.smim.2016.05.006

2. Zhang T, Qiu L, Sun Z, Wang L, Zhou Z, Liu R, et al. The specifically enhanced cellular immune responses in Pacific oyster (Crassostrea gigas) against secondary challenge with Vibrio splendidus. Dev Comp Immunol (2014) 45:141–50. doi:10.1016/j.dci.2014.02.015

3. Pope EC, Powell A, Roberts EC, Shields RJ, Wardle R, Rowley AF. Enhanced cellular immunity in shrimp (Litopenaeus vannamei) after “vaccination”. PLoS One (2011) 6:e20960. doi:10.1371 journal.pone.0020960

4. Wu G, Li M, Liu Y, Ding Y, Yi Y. The specificity of immune priming in silkworm, Bombyx mori, is mediated by the phagocytic ability of granular cells. J Insect Physiol (2015) 81:60–8. doi:10.1016/j.jinsphys.2015.07.004

5. Kurtz J. Specific memory within innate immune systems. Trends Immunol (2005) 26:186–92. doi:10.1016/j.it.2005.02.001

6. Diana Boraschi and Paola Italiani. Innate Immune Memory: Time for Adopting a Correct Terminology. Front. Immunol., 19 April 2018 | https://doi.org/10.3389/fimmun.2018.00799

7. Agrawal AA, Laforsch C, Tollrian R. Transgenerational induction of defences in animals and plants. Nature (1999) 401:60–3. doi:10.1038/43425

8. Cynthia Castro-Vargas et al. Potential Mechanism Related to Immune Priming within But Not across Generations. Front. Microbiol., 28 March 2017. doi.org/10.3389/fmicb.2017.00473
9. Mihai G. Netea, Jessica Quintin, Jos W.M. van der Meer. Trained Immunity: A Memory for Innate Host Defense. PERSPECTIVE | VOLUME 9, ISSUE 5, P355-361, MAY 19, 2011 doi.org/10.1016/j.chom.2011.04.006

10. Rodolphe Barrangou. The Roles of CRISPR-Cas Systems in Adaptive Immunity and Beyond. Current Opinion in Immunology. 32: 36–41. doi:10.1016/j.coi.2014.12.008

11. Fire A., Xu S., Montgomery M., Kostas S., Driver S., Mello C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998. Vol. 391, 6669. P. 806—811. doi:10.1038/35888

12. Byung-Chun Yoo et al. A Systemic Small RNA Signaling System in Plants. Plant Cell. 2004 Aug; 16(8): 1979–2000. doi: 10.1105/tpc.104.023614

13. Shou-Wei Ding and Olivier Voinnet. Antiviral Immunity Directed by Small RNAs. Cell. 2007 Aug 10; 130(3): 413–426. doi: 10.1016/j.cell.2007.07.039

14. Cordula Kemp and Jean-Luc Imler. Antiviral immunity in drosophila. Curr Opin Immunol. 2009 Feb; 21(1): 3–9. Published online 2009 Feb 14. doi: 10.1016/j.coi.2009.01.007

15. Peter Sarkies, Eric A Miska. RNAi Pathways in the Recognition of Foreign RNA: Antiviral Responses and Host-Parasite Interactions in Nematodes. Biochem Soc Trans. 2013 Aug;41(4):876-80. doi: 10.1042/BST20130021.

16. RoghniAlyari and Shou-Wei Ding. RNA-based viral immunity initiated by the Dicer family of host immune receptors. Immunol Rev. 2009 Jan; 227(1): 176–188. doi: 10.1111/j.1600-065X.2008.00722.

17. Pierre Maillard, Annemarthe G van der Veen, Enzo Z Poirier, Caetano Reis e Sousa. Slicing and dicing viruses: antiviral RNA interference in mammals. EMBO J. 2019. 38:e100941 doi.org/10.15252/embj.2018100941

18. Zhang Y, Li Y. Regulation of innate receptor pathways by microRNAs. Sci China Life Sci. 2013 Jan;56(1):13-8. doi: 10.1007/s11427-012-4428-2. Epub 2012 Dec 27.

19. Yingke Li, Xueyin Shi. MicroRNAs in the Regulation of TLR and RIG-I Pathways. Cell Mol Immunol. 2013 Jan;10(1):65-71. doi: 10.1038/cmi.2012.55.

20. Jiaxi Wu, Zhijian J Chen. Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids. Annu Rev Immunol. 2014;32:461-88. doi: 10.1146/annurev-immunol-032713-120156.

21. Annemarthe G van der Veen et al. The RIG-I-like receptor LGP2 inhibits Dicer-dependent processing of long double-stranded RNA and blocks RNA interference in mammalian cells. EMBO J. 2018 Feb 15; 37(4): e97479. doi: 10.15252/embj.201797479

22. lan G. Cannell, Yi Wen Kong, Martin Bushell. How do microRNAs regulate gene expression? BiochemSoc Trans (2008) 36 (6): 1224–1231. https://doi.org/10.1042/BST061224

23. Laleh Habibi and HamzehtSalmani. Pivotal Impacts of Retrotransposon Based Invasive RNAs on Evolution. Front. Microbiol., 10 October 2017 | doi.org/10.3389/fmicb.2017.01957

24. W Wei, T A Morrish, R S Alisch, J V Moran. A Transient Assay Reveals That Cultured Human Cells Can Accommodate Multiple LINE-1 Retrotransposition Events. Anal Biochem . 2000 Sep 10;284(2):435-8. doi: 10.1006/abio.2000.4675

25. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. (February 2001). "Initial sequencing and analysis of the human genome". Nature. 409 (6822): 860–921. doi:10.1038/35057062

26. Wicker T, Sabot F, Hua-Van A, Bennetzen JL, Capy P, Chalhoub B, Flavell A, Leroy P, Morgante M, Panaud O, Paux E, SanMiguel P, Schulman AH (December 2007). "A unified classification system for eukaryotic transposable elements". Nature Reviews. Genetics. 8 (12): 973–82. doi:10.1038/nrg2165

27. Song, Ji-Joon, Stephanie K. Smith, Gregory J. Hannon, Leemor Joshua-Tor. 2004. Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity. Science 305: 1434-1437.

28. Meister, Gunter, and Thomas Tuschi. 2004. Mechanisms of Gene Silencing by Double Stranded RNA. Nature 431: 343-349.
29. K Onomoto, M Yoneyama, T Fujita. Regulation of Antiviral Innate Immune Responses by RIG-I Family of RNA Helicases. Curr Top Microbiol Immunol. 2007;316:193-205. doi: 10.1007/978-3-540-71329-6_10.

30. Agnieszka Jabłońska, Edyta Paradowska. Role of the RIG-I-like Receptors in Antiviral Response. Postepy Hig Med Dosw (Online). 2014 Jan 2;68:541-56. DOI: 10.5604/17322693.1102281

31. Amir Apelbaum, Gani Yarden, Shira Warszawski, Daniel Harari, and Gideon Schreiber. Type I Interferons Induce Apoptosis by Balancing cFLIP and Caspase-8 Independent of Death Ligands. Mol Cell Biol. 2013 Feb; 33(4): 800–814. doi: 10.1128/MCB.01430-12

32. Kevin P. Kotredes and Ana M. Gamero. Interferons as Inducers of Apoptosis in Malignant Cells. J Interferon Cytokine Res. 2013 Apr; 33(4): 162–170. doi: 10.1089/jir.2012.0110

33. David E. Levy. Whence Interferon? Variety in the Production of Interferon in Response to Viral Infection. J Exp Med. 2002 Feb 18; 195(4): f15–f18. doi: 10.1084/jem.20020075

34. Daniel B. Stetson and Ruslan Medzhitov. Type I Interferons in Host Defense. Immunology. Volume 25, Issue 3, September 2006, Pages 373-381. doi.org/10.1016/j.immuni.2006.08.007

35. Julie Eggengberger, Daniel Blanco-Melo, Maryline Panis, Kristen J. BRENNAND, and Benjamin R. ten Oever. Type I interferon response impairs differentiation potential of pluripotent stem cells. PNAS January 22, 2019 116 (4) 1384-1393; doi.org/10.1073/pnas.1812449116

36. Irun R. Cohen and Douglas B. Youngb. Autoimmunity, microbial immunity and the immunological homunculus. Immunology Today. Volume 12, Issue 4, April 1991, Pages 105-110. doi.org/10.1016/0167-5699(91)90093-9

37. А. М. Зайчик, А. Б. Полетаев, Л. П. Чурилов. РАСПОЗНАВАНИЕ «СВОЕГО» И ВЗАИМОДЕЙСТВИЕ СО «СВОИМ» КАК ОСНОВНАЯ ФОРМА АКТИВНОСТИ АДАПТИВНОЙ ИММУННОЙ СИСТЕМЫ. Вестник СПбГУ. Сер. 11. 2013. Вып. 1 УДК 612.017.1+616.097+576.8

38. Галактионов В.Г. Проблемы эволюционной биологии. Медицинская иммунология. 2004, том 6, №3-5.

39. Hawkes R. A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42, 465–482. DOI: 10.1083/iecb.1964.44

40. Maria K. Smatti, Asmaa A. Al Thani, and Hadi M. Yassine. Viral-Induced Enhanced Disease Illness. Front Microbiol. 2018; 9: 2991. doi: 10.3389/fmicb.2018.02991

41. Vennema Harry; Poland Amy; Foley Janet; Pedersen Niels C. "Feline Infectious Peritonitis Viruses Arise by Mutation from Endemic Feline Enteric Coronavirus". Virology. 1998. 243 (1): 150–157. doi:10.1006/viro.1998.9045.

42. Tirado S. M. and Yoon K. J. "Antibody-dependent enhancement of virus infection and disease". Viral Immunology. 2003. 16 (1): 69–86. doi:10.1089/088282403763635465

43. Khandia R.; Munjal A.; Dhama K.; Karthik K.; Tiwari R.; Malik Y. S.; Singh R. K.; Chaicumpa W. "Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection". Frontiers in Immunology. 2018. 9: 597. doi:10.3389/fimmu.2018.00597

44. Iwasaki Akiko; Yang Yexin. "The potential danger of suboptimal antibody responses in COVID-19". Nature Reviews Immunology. 2020-04-21. doi:10.1038/s41577-020-0321-6

45. Tseng C. et al. "Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus". PLOS ONE. 2012.7 (4): e35421. Bibcode:2012PLoSO...735421T. doi:10.1371/journal.pone.0035421

46. Liu L. et al. "Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection". JCI Insight. 2019. 4 (4). doi:10.1172/jci.insight.123158

47. Wan Y. et al. "Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry". Journal of Virology. 2020. 94 (5). doi:10.1128/JVI.02015-19

48. Yip Ming S; Cheung Chung Y; Li Ping H; Bruzzone Roberto; Peiris JS Malik; Jaume Martial. "Investigation of Antibody-Dependent Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of SARS". BMC Proceedings. 2011-01-10. 5 (S1). doi:10.1186/1753-5661-5-s1-p80
49. Lynne Peeples. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci U S A. 2020 Apr 14; 117(15): 8218–8221. doi: 10.1073/pnas.2005456117

50. Peter J. Hotez, David B. Corry and Maria Elena Bottazzi. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 Apr 28: 1–2. doi: 10.1038/s41577-020-0323-4